Physician profile
Xue Yang
NPI 1841854015
$6,061.82
in general payments reported to CMS, 2019-2025
39 companies · $2,446 in 2025
The $2,446 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,092 · 2024: $2,524 · 2025: $2,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,960 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,959.50 |
| Education | $102.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $762.13 | 2023-2025 | Duopa |
| Pfizer INC. | $752.25 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $484.82 | 2023-2025 | Ingrezza, Ongentys |
| Vanda Pharmaceuticals INC. | $408.70 | 2025 | Ponvory |
| Emd Serono, INC. | $316.12 | 2023-2025 | Mavenclad, Mavenclad |
| Teva Pharmaceuticals USA, INC. | $256.72 | 2023-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $241.18 | 2023-2025 | |
| Sk Life Science, INC. | $232.49 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $201.18 | 2023-2025 | Epidiolex |
| Ucb, INC. | $196.59 | 2023-2025 | Rystiggo, Briviact |
| Genentech USA, INC. | $194.36 | 2023-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Novartis Pharmaceuticals Corporation | $173.26 | 2023-2025 | |
| Biogen, INC. | $166.57 | 2023-2024 | Vumerity, Tysabri, Skyclarys |
| Lundbeck LLC | $159.82 | 2023-2025 | Vyepti |
| Mallinckrodt Hospital Products INC. | $155.83 | 2024-2025 | Acthar |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $149.31 | 2023 | Ultomiris, Soliris |
| Otsuka America Pharmaceutical, INC. | $119.35 | 2023-2025 | Rexulti, Nuedexta |
| Argenx US, INC. | $110.01 | 2024-2025 | Vyvgart |
| Lilly USA, LLC | $94.17 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Neurelis, INC. | $93.68 | 2023-2025 | Valtoco |
| Csl Behring | $89.68 | 2023-2025 | Hizentra |
| Tg Therapeutics, INC. | $89.46 | 2023-2025 | |
| Cycle Pharmaceuticals INC | $85.39 | 2024-2025 | Tascenso Odt, Bafiertam |
| Ani Pharmaceuticals, INC. | $70.52 | 2024-2025 | Purified Cortrophin Gel |
| Octapharma USA, INC. | $66.90 | 2024 | Panzyga |
| Amneal Pharmaceuticals LLC | $43.84 | 2023-2025 | Crexont, Rytary |
| Genzyme Corporation | $41.07 | 2024-2025 | |
| Grifols USA, LLC | $34.78 | 2025 | Gamunex-C |
| Merck Sharp & Dohme LLC | $34.20 | 2024 | Welireg |
| Xeris Pharmaceuticals, INC. | $32.80 | 2025 | Keveyis |
| Janssen Biotech, INC. | $29.31 | 2025 | |
| Neuropace, INC. | $28.86 | 2023-2025 | |
| Livanova USA, INC. | $27.39 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Catalyst Pharmaceuticals, INC. | $25.34 | 2023 | Firdapse |
| Astrazeneca Pharmaceuticals LP | $24.98 | 2024 | Andexxa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.39 | 2025 | Caplyta |
| Alnylam Pharmaceuticals INC. | $19.26 | 2024 | Onpattro |
| Ipsen Biopharmaceuticals, INC | $15.90 | 2025 | Dysport |
| Harmony Biosciences LLC | $14.21 | 2023 | Wakix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xue Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.